Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Rating) was the target of a significant drop in short interest in May. As of May 31st, there was short interest totalling 34,410,000 shares, a drop of 20.5% from the May 15th total of 43,310,000 shares. Based on an average daily trading volume, of 5,830,000 shares, the days-to-cover ratio is presently 5.9 days.
INO stock traded down $0.02 during trading hours on Thursday, hitting $1.51. The company’s stock had a trading volume of 191,626 shares, compared to its average volume of 5,344,951. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $344.71 million, a PE ratio of -0.97 and a beta of 0.82. Inovio Pharmaceuticals has a 12 month low of $1.40 and a 12 month high of $9.96. The stock has a 50 day moving average price of $2.35 and a two-hundred day moving average price of $3.68.
Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). Inovio Pharmaceuticals had a negative return on equity of 76.48% and a negative net margin of 20,479.29%. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.66 million. During the same quarter last year, the business posted ($0.27) EPS. The firm’s revenue was down 46.4% compared to the same quarter last year. Sell-side analysts expect that Inovio Pharmaceuticals will post -1.19 earnings per share for the current year.
Several brokerages recently weighed in on INO. Cantor Fitzgerald dropped their target price on Inovio Pharmaceuticals from $6.00 to $3.00 in a report on Wednesday, May 11th. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 2nd. Oppenheimer lowered Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 11th. Finally, StockNews.com raised shares of Inovio Pharmaceuticals to a “sell” rating in a report on Monday, May 23rd. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $11.80.
Inovio Pharmaceuticals Company Profile (Get Rating)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
- Get a free copy of the StockNews.com research report on Inovio Pharmaceuticals (INO)
- The Q2 Earnings Season Could Be A Bloodbath
- The Institutions Turn The Tide For Jabil
- Commercial Metals Company Is Ready To Rebound
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.